PCSA - Processa Pharmaceuticals - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-4.007M

Cash

8.92M

Avg Qtr Burn

-2.00M

Short % of Float

1.96%

Insider Ownership

12.11%

Institutional Own.

3.72%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
NGC- Gemcitabine (PCS3117) Details Pancreatic cancer, Cancer, Non-small cell lung carcinoma, Gall bladder cancer	Phase 2/3 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
NGC- Capecitabine (PCS6422) Details Solid tumor/s, Cancer, Colorectal cancer , Pancreatic cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PCS12852 Details Opioid induced constipation, Post-op GI Dysfunction	Phase 2a Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
PCS499 Details Ulcerative Necrobiosis Lipoidica	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.